A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Completed · Phase 1

Conditions studied: Insulin Resistance, Obesity

In brief

The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.

Key facts

Study ID

NCT00398619

Run by

Incyte Corporation

Starts

2006-11-01

Expected to finish

2007-03-01

Last updated by the study team

2012-01-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female subjects between 18 years and 65 years of age.
• BMI between 30 and 42 kg/m2, inclusive.
• FPG <126 mg/dL

You may not qualify if…

• Meet criteria for diagnosis of diabetes mellitus at the screening evaluation, female subjects with a history of gestational diabetes are permitted.
• Are receiving oral antidiabetic agents within the 3 months prior to screening.

Where it is running

• Study site — Beverly Hills, California, United States
• Study site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.